Mr. James Howard-Tripp reports

AMENDED PRESS RELEASE: STAGEZERO LIFE SCIENCES FINANCIALS UPDATE

Stagezero Life Sciences Ltd. has intended to issue its audited financial statements for the calendar year 2019, management's discussion and analysis for the three-month and 12-month periods to Dec. 31, 2019, and the annual information form on March 30, 2020, in line with its normal reporting calendar. The company now, however, due to disruption of the audit process caused by the COVID-19 crisis, intends to rely on exemptions recently granted by Canadian securities regulatory authorities that allow it to delay the issue of the 2019 financial statements, the 2019 MD&A and the 2019 AIF.

Without the exemptions, the company would be required to issue and file its 2019 annual financial statements, 2019 MD&A and 2019 AIF by March 30, 2020. In response to the global COVID-19 pandemic, securities regulatory authorities in Canada have granted blanket exemptions, allowing companies an additional 45 days in which to complete their regulatory filings.

The company intends to rely on the exemptions to provide its board of directors and its recently appointed auditor adequate time to complete the full-year audit. The company and its auditor are making every effort to issue and file the 2019 annual financial statements, the 2019 MD&A and the 2019 AIF at the earliest opportunity.

The company's management and other insiders will continue to observe a trading blackout consistent with the principles contained in Canadian National Policy 11-207 (Failure to File Cease Orders and Revocations in Multiple Jurisdictions) until such time as the 2019 financial statements, the 2019 MD&A and the 2019 AIF are filed.

The company confirms all material developments have been disclosed through press releases, and there have been no material business developments that have not been disclosed since the company's financials and MD&A for the third quarter ended Sept. 30, 2019.

About Stagezero Life Sciences Ltd.

Stagezero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle, its next-generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on the company's proven and proprietary Sentinel principle technology platform, which has been validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer, with further validation currently under way. In addition to building a pipeline of products for early cancer detection, the company operates a CAP-accredited and CLIA-certified reference laboratory based in Richmond, Va., that offers the ColonSentry test, as well as licensed biomarker tests for breast and prostate cancers.

We seek Safe Harbor.